232 related articles for article (PubMed ID: 22041697)
1. [Genetic polymorphisms of SLCO1B1 for drug pharmacokinetics and its clinical implications].
Takane H
Yakugaku Zasshi; 2011; 131(11):1589-94. PubMed ID: 22041697
[TBL] [Abstract][Full Text] [Related]
2. SLCO1B1 polymorphism and oral antidiabetic drugs.
Kalliokoski A; Neuvonen PJ; Niemi M
Basic Clin Pharmacol Toxicol; 2010 Oct; 107(4):775-81. PubMed ID: 20406215
[TBL] [Abstract][Full Text] [Related]
3. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
Niemi M; Backman JT; Kajosaari LI; Leathart JB; Neuvonen M; Daly AK; Eichelbaum M; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2005 Jun; 77(6):468-78. PubMed ID: 15961978
[TBL] [Abstract][Full Text] [Related]
4. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.
Kivistö KT; Niemi M
Pharm Res; 2007 Feb; 24(2):239-47. PubMed ID: 17177112
[TBL] [Abstract][Full Text] [Related]
5. Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
Kalliokoski A; Backman JT; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2008 Nov; 18(11):937-42. PubMed ID: 18854776
[TBL] [Abstract][Full Text] [Related]
6. Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1).
Lee HH; Ho RH
Br J Clin Pharmacol; 2017 Jun; 83(6):1176-1184. PubMed ID: 27936281
[TBL] [Abstract][Full Text] [Related]
7. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake.
Niemi M; Pasanen MK; Neuvonen PJ
Pharmacol Rev; 2011 Mar; 63(1):157-81. PubMed ID: 21245207
[TBL] [Abstract][Full Text] [Related]
8. The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.
Kalliokoski A; Neuvonen M; Neuvonen PJ; Niemi M
Br J Clin Pharmacol; 2008 Dec; 66(6):818-25. PubMed ID: 18823304
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1).
van de Steeg E; van der Kruijssen CM; Wagenaar E; Burggraaff JE; Mesman E; Kenworthy KE; Schinkel AH
Drug Metab Dispos; 2009 Feb; 37(2):277-81. PubMed ID: 19022939
[TBL] [Abstract][Full Text] [Related]
10. Cyclosporine markedly raises the plasma concentrations of repaglinide.
Kajosaari LI; Niemi M; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
Clin Pharmacol Ther; 2005 Oct; 78(4):388-99. PubMed ID: 16198658
[TBL] [Abstract][Full Text] [Related]
11. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.
Daka A; Dimovski A; Kapedanovska A; Vavlukis M; Eftimov A; Labachevski N; Jakjovski K; Geshkovska MN; Nebija D; Mladenovska K
Pharmazie; 2015 Jul; 70(7):480-8. PubMed ID: 26373210
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.
Ieiri I; Higuchi S; Sugiyama Y
Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):703-29. PubMed ID: 19442037
[TBL] [Abstract][Full Text] [Related]
13. Impact of OATP transporters on pharmacokinetics.
Kalliokoski A; Niemi M
Br J Pharmacol; 2009 Oct; 158(3):693-705. PubMed ID: 19785645
[TBL] [Abstract][Full Text] [Related]
14. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population.
Pasanen MK; Backman JT; Neuvonen PJ; Niemi M
Eur J Clin Pharmacol; 2006 Jun; 62(6):409-15. PubMed ID: 16758257
[TBL] [Abstract][Full Text] [Related]
15. Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele.
Takane H; Miyata M; Burioka N; Kurai J; Fukuoka Y; Suyama H; Shigeoka Y; Otsubo K; Ieiri I; Shimizu E
Ther Drug Monit; 2007 Oct; 29(5):666-8. PubMed ID: 17898662
[TBL] [Abstract][Full Text] [Related]
16. Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism.
Kalliokoski A; Backman JT; Kurkinen KJ; Neuvonen PJ; Niemi M
Clin Pharmacol Ther; 2008 Oct; 84(4):488-96. PubMed ID: 19238654
[TBL] [Abstract][Full Text] [Related]
17. Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer.
Han JY; Lim HS; Shin ES; Yoo YK; Park YH; Lee JE; Kim HT; Lee JS
Lung Cancer; 2008 Jan; 59(1):69-75. PubMed ID: 17766002
[TBL] [Abstract][Full Text] [Related]
18. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.
Niemi M; Pasanen MK; Neuvonen PJ
Clin Pharmacol Ther; 2006 Oct; 80(4):356-66. PubMed ID: 17015053
[TBL] [Abstract][Full Text] [Related]
19. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.
Romaine SP; Bailey KM; Hall AS; Balmforth AJ
Pharmacogenomics J; 2010 Feb; 10(1):1-11. PubMed ID: 19884908
[TBL] [Abstract][Full Text] [Related]
20. Transporters as a determinant of drug clearance and tissue distribution.
Shitara Y; Horie T; Sugiyama Y
Eur J Pharm Sci; 2006 Apr; 27(5):425-46. PubMed ID: 16488580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
